BR112017006240A2 - novos compostos - Google Patents

novos compostos

Info

Publication number
BR112017006240A2
BR112017006240A2 BR112017006240A BR112017006240A BR112017006240A2 BR 112017006240 A2 BR112017006240 A2 BR 112017006240A2 BR 112017006240 A BR112017006240 A BR 112017006240A BR 112017006240 A BR112017006240 A BR 112017006240A BR 112017006240 A2 BR112017006240 A2 BR 112017006240A2
Authority
BR
Brazil
Prior art keywords
new compounds
pyrazole
salt
compound
formula
Prior art date
Application number
BR112017006240A
Other languages
English (en)
Inventor
Paul Hancock Ashley
Martin Pritchard John
Howard James Campbell-Crawford Matthew
Andrew Anderson Niall
Alexandrou Procopiou Panayiotis
Lemma Seble
John Fawcett Macdonald Simon
Swanson Stephen
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of BR112017006240A2 publication Critical patent/BR112017006240A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

resumo "novos compostos" (i) composto da fórmula (i) ou um sal do mesmo, em que r1 representa um átomo de hidrogênio, um grupo ciclopropila ou um anel pirazol, o pirazol sendo opcionalmente substituído por um ou dois grupos metila.
BR112017006240A 2014-09-26 2015-09-22 novos compostos BR112017006240A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1417018.7A GB201417018D0 (en) 2014-09-26 2014-09-26 Novel compounds
PCT/EP2015/071798 WO2016046241A1 (en) 2014-09-26 2015-09-22 Novel compounds

Publications (1)

Publication Number Publication Date
BR112017006240A2 true BR112017006240A2 (pt) 2017-12-12

Family

ID=51901174

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017006240A BR112017006240A2 (pt) 2014-09-26 2015-09-22 novos compostos

Country Status (12)

Country Link
US (1) US10004724B2 (pt)
EP (1) EP3197895B1 (pt)
JP (1) JP6672276B2 (pt)
KR (1) KR20170054413A (pt)
CN (1) CN107074850A (pt)
AU (1) AU2015320874A1 (pt)
BR (1) BR112017006240A2 (pt)
CA (1) CA2962319A1 (pt)
ES (1) ES2796235T3 (pt)
GB (1) GB201417018D0 (pt)
RU (1) RU2017114352A (pt)
WO (1) WO2016046241A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417094D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
MA46745A (fr) 2016-11-08 2021-03-31 Bristol Myers Squibb Co Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
HRP20220990T1 (hr) 2016-11-08 2022-11-11 Bristol-Myers Squibb Company 3-supstituirane propionske kiseline kao inhibitori alfa v integrina
CA3042684A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Azole amides and amines as .alpha.v integrin inhibitors
KR102506324B1 (ko) 2016-11-08 2023-03-03 브리스톨-마이어스 스큅 컴퍼니 알파 v 인테그린 억제제로서의 시클로부탄- 및 아제티딘-함유 모노 및 스피로시클릭 화합물
US10717736B2 (en) * 2016-11-08 2020-07-21 Bristol-Myers Squibb Company Pyrrole amides as alpha V integrin inhibitors
WO2018119087A1 (en) 2016-12-23 2018-06-28 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
KR102605460B1 (ko) 2017-02-28 2023-11-22 모픽 테라퓨틱, 인코포레이티드 αvβ6 인테그린 억제제
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
SG11202004077WA (en) 2017-11-07 2020-05-28 Bristol Myers Squibb Co Pyrrolopyrazine derivatives as alpha v integrin inhibitors
MX2021002181A (es) 2018-08-29 2021-07-15 Morphic Therapeutic Inc Inhibicion de la integrina alfa v beta 6.

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508323A (ja) * 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
AU739811B2 (en) 1997-12-17 2001-10-18 Merck & Co., Inc. Integrin receptor antagonists
HUP0302468A2 (hu) 1999-06-02 2003-11-28 Merck & Co., Inc. Alfa V integrin receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények
CA2376077A1 (en) 1999-06-23 2000-12-28 Merck & Co., Inc. Integrin receptor antagonists
EP1229910A4 (en) * 1999-10-04 2003-10-01 Merck & Co Inc integrin
AU777919B2 (en) 1999-11-08 2004-11-04 Merck Sharp & Dohme Corp. Process and intermediates for the preparation of imidazolidinone alpha V integrin antagonists
JP2004511434A (ja) * 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
AU2001277935B2 (en) 2000-07-26 2005-08-04 Merck & Co., Inc. Alpha v integrin receptor antagonists
WO2002022616A2 (en) 2000-09-14 2002-03-21 Merck & Co., Inc. Alpha v integrin receptor antagonists
AU2002246757B2 (en) 2001-01-03 2006-02-02 Merck & Co., Inc. Methods and compositions for treating periodontal disease
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
WO2004058254A1 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
SI2139882T1 (sl) 2007-03-23 2014-03-31 Amgen Inc. 3-substituirani kinolinski ali kinoksalinski derivati in njihoba uporaba kot inhibitorji fosfatidilinozitol 3-kinaze (pi3k)
JP2011500823A (ja) 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
WO2015048819A1 (en) 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
ES2892954T3 (es) 2015-02-19 2022-02-07 Ocuterra Therapeutics Inc Derivados fluorados del ácido 3-(2-oxo-3-(3-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)propil)imidazolidin-1-il)propanoico y usos de los mismos
US10214522B2 (en) 2015-03-10 2019-02-26 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds

Also Published As

Publication number Publication date
US20170290818A1 (en) 2017-10-12
JP2017528506A (ja) 2017-09-28
CA2962319A1 (en) 2016-03-31
CN107074850A (zh) 2017-08-18
RU2017114352A (ru) 2018-10-26
AU2015320874A1 (en) 2017-03-09
US10004724B2 (en) 2018-06-26
WO2016046241A1 (en) 2016-03-31
ES2796235T3 (es) 2020-11-26
EP3197895A1 (en) 2017-08-02
EP3197895B1 (en) 2020-03-11
JP6672276B2 (ja) 2020-03-25
KR20170054413A (ko) 2017-05-17
GB201417018D0 (en) 2014-11-12

Similar Documents

Publication Publication Date Title
BR112017006240A2 (pt) novos compostos
BR112017006253A2 (pt) novos compostos
CO2018004124A2 (es) Compuestos heterocíclicos
MD3464249T2 (ro) Derivați carbonucleozidici substituiţi utili în calitate de agenți anticanceroşi
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
TW201613911A (en) Heterocyclic compounds and uses thereof
BR112016029333A2 (pt) síntese de compostos de carbamoilpiridona policíclico
CR20160098A (es) Polimorfo de los inhibidores de la syk
BR112017006251A2 (pt) novos compostos
BR112016028773A2 (pt) processos para preparação de compostos antivirais
CO2017000332A2 (es) Coŵpuestos heterocíclicos como receptores huérfanos relacionados con retinoide gamma-t (ror γt)
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
BR112017019286A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável deste
EA201791304A1 (ru) Производные изохинолина для лечения вич
MA40302B1 (fr) Dérivés de carbazole
CL2015002027A1 (es) Compuestos quimicos
EA201891278A1 (ru) Гетероциклические индолы для применения при инфекции, вызванной вирусом гриппа
EA201790496A1 (ru) Соединения 1-алкил-6-оксо-1,6-дигидропиридин-3-ила и применение в качестве модуляторов sgrm
AU2015309863A8 (en) Azaindole derivative having AMPK-activating effect
CL2018001067A1 (es) Compuesto piranodipiridínico.
CL2017000151A1 (es) Derivados de piridona
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
BR112017019850A2 (pt) ?processo melhorado para a preparação de apremilast?
EA201691999A1 (ru) Новые сульфониламинобензамидные соединения
BR112016027455A2 (pt) moduladores ppar

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]